Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 3/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.56 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.56 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.56 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | VCP | P55072 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | TLR4 | O00206 | 1/20 | 0.44 |
| ▸ | TLR2 | O60603 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29828887 | 1.00 | FBP1 (0.57) | FBP1CYP1A2CYP1A1CYP1B1PRMT1 | |
| SCHEMBL1437116 | 1.00 | FBP1 (0.57) | FBP1CYP1A2CYP1A1CYP1B1PRMT1 | |
| SCHEMBL29434365 | 1.00 | FBP1 (0.57) | FBP1CYP1A2CYP1A1CYP1B1PRMT1 | |
| SCHEMBL458371 | 0.88 | FBP1 (0.57) | FBP1CYP1A2CYP1A1CYP1B1PRMT1 | |
| SCHEMBL459698 | 0.88 | FBP1 (0.57) | FBP1CYP1A2CYP1A1CYP1B1PRMT1 | |
| SCHEMBL16785469 | 0.83 | FBP1 (0.58) | FBP1CYP1A2CYP1A1CYP1B1PRMT1 | |
| SCHEMBL3100263 | 0.83 | CYP1A2 (0.66) | FBP1CYP1A2CYP1A1CYP1B1PRMT1 | |
| SCHEMBL29434229 | 0.83 | FBP1 (0.58) | FBP1CYP1A2CYP1A1CYP1B1PRMT1 | |
| SCHEMBL18106684 | 0.83 | FBP1 (0.58) | FBP1CYP1A2CYP1A1CYP1B1PRMT1 | |
| SCHEMBL3100253 | 0.83 | CYP1A2 (0.66) | FBP1CYP1A2CYP1A1CYP1B1PRMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110997661-B | Cyclopropyl ureaplatin 2 receptor and formyl peptide 1 receptor agonists | 百时美施贵宝公司 | 2023-03-31 | — | — | CN | disclosed |
| US-11261155-B2 | Urea derivative or pharmacologically acceptable salt thereof | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2022-03-01 | — | — | US | disclosed |
| US-11180490-B2 | Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-11-23 | — | — | US | disclosed |
| US-11180490-B2 | Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-11-23 | — | — | US | disclosed |
| EP-3634958-B1 | CYCLOPROPYL UREA FORMYL PEPTIDE 2 RECEPTOR AND FORMYL PEPTIDE 1 RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-07-21 | — | — | EP | disclosed |
| EP-3634958-B1 | CYCLOPROPYL UREA FORMYL PEPTIDE 2 RECEPTOR AND FORMYL PEPTIDE 1 RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-07-21 | — | — | EP | disclosed |
| US-20210107869-A1 | Urea Derivative Or Pharmacologically Acceptable Salt Thereof | KYORIN SEIYAKU KK (JP) | 2021-04-15 | — | — | US | disclosed |
| US-20210107869-A1 | Urea Derivative Or Pharmacologically Acceptable Salt Thereof | KYORIN SEIYAKU KK (JP) | 2021-04-15 | — | — | US | disclosed |
| US-10696630-B2 | Urea derivative or pharmacologically acceptable salt thereof | KYORIN PHARMACEUTICALS CO., LTD. (JP) | 2020-06-30 | — | — | US | disclosed |
| US-10696630-B2 | Urea derivative or pharmacologically acceptable salt thereof | KYORIN PHARMACEUTICALS CO., LTD. (JP) | 2020-06-30 | — | — | US | disclosed |
| WO-2010025451-A2 | 5,8-DIFLUORO-4-(2-(4-(HETEROARYLOXY)-PHENYL)ETHYLAMINO)QUINAZOLINES AND THEIR USE AS AGROCHEMICALS | DOW AGROSCIENCES LLC (US) | 2010-03-04 | — | — | WO | disclosed |
| WO-2010025451-A2 | 5,8-DIFLUORO-4-(2-(4-(HETEROARYLOXY)-PHENYL)ETHYLAMINO)QUINAZOLINES AND THEIR USE AS AGROCHEMICALS | DOW AGROSCIENCES LLC (US) | 2010-03-04 | — | — | WO | disclosed |
| EP-1409468-B9 | GUANIDINOBENZAMIDES AS MC4-R AGONISTS | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2009-07-29 | — | — | EP | disclosed |
| EP-1409468-B1 | GUANIDINOBENZAMIDES AS MC4-R AGONISTS | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-11-12 | — | — | EP | disclosed |
| US-6995269-B2 | Guanidinobenzamides | CHIRON CORPORATION (US) | 2006-02-07 | — | — | US | disclosed |
| EP-1409468-A2 | GUANIDINOBENZAMIDES AS MC4-R AGONISTS | CHIRON CORPORATION (US) | 2004-04-21 | — | — | EP | disclosed |
| US-6638927-B2 | Melanocortin-4 receptor (MC4-R) agonists; treating obesity or diabetes; 4-((N-cyclohexyl-3,5-dimethyl-piperazine-1-carboximidoyl)-amino)-N-(2-(2,4 -dichlorophenyl) -ethyl)-benzamide for example | CHIRON CORPORATION | 2003-10-28 | — | — | US | disclosed |
| US-20030199499-A1 | Novel guanidinobenzamides | CHIRON CORPORATION | 2003-10-23 | — | — | US | disclosed |
| US-20020137939-A1 | Melanocortin-4 receptor (MC4-R) agonists; treating obesity or diabetes; 4-((N-cyclohexyl-3,5-dimethyl-piperazine-1-carboximidoyl)-amino)-N-(2-(2,4 -dichlorophenyl)-ethyl)-benzamide for example | CHIRON CORPORATION | 2002-09-26 | — | — | US | disclosed |
| WO-2002018327-A2 | GUANIDINOBENZAMIDES AS MC4-R AGONISTS | CHIRON CORPORATION (US) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11180490-B2 | Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists | FPR1, FPR2, FPR3 | FBP1 1285/4885CYP1A2 3223/4885CYP1A1 2528/4885 |
| US-10696630-B2 | Urea derivative or pharmacologically acceptable salt thereof | FPR1, FPR2, FPR3 | FBP1 898/4885CYP1A2 3393/4885CYP1A1 2591/4885 |
| US-20210107869-A1 | Urea Derivative Or Pharmacologically Acceptable Salt Thereof | FPR1, FPR2, FPR3 | FBP1 898/4885CYP1A2 3393/4885CYP1A1 2591/4885 |
| US-20030199499-A1 | Novel guanidinobenzamides | GUCY1B2, GPR119, GUCY1B1 | FBP1 2405/4885CYP1A2 1021/4885CYP1A1 1757/4885 |
| US-20020137939-A1 | Melanocortin-4 receptor (MC4-R) agonists; treating obesity or diabetes; 4-((N-cyclohexyl-3,5-dimethyl-piperazine-1-carboximidoyl)-amino)-N-(2-(2,4 -dichlorophenyl)-ethyl)-benzamide for example | MC4R, MC5R, MC3R | FBP1 4335/4885CYP1A2 1403/4885CYP1A1 1500/4885 |
| US-11261155-B2 | Urea derivative or pharmacologically acceptable salt thereof | FPR1, FPR2, FPR3 | FBP1 898/4885CYP1A2 3393/4885CYP1A1 2591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.